# Satio Inc.

Canonical: https://abierto.us/vendors/satio-inc-h8wfvflrqyn3

- UEI: H8WFVFLRQYN3
- CAGE: 9DLB1
- Location: Boston, MA
- Awards in window: 2 (7 transactions), -$536,094 obligated, March 7, 2024 to February 3, 2026

## Awarding agencies

- National Institutes of Health: 1 awards, $0
- Office of Assistant Secretary for Preparedness and Response: 1 awards, -$536,094

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $0
- 541714 Research and Development in Biotechnology (except Nanobiotechnology): -$536,094

## Competition

- Full and Open Competition After Exclusion of Sources: 1 awards
- Full and Open Competition: 1 awards

## Largest awards

- 75N91023C00059 (definitive contract): $0, NIH NCI. Development of Digital Satiorx, a Very Low Cost Remotely Controllable Disposable Microneedle Transdermal Drug Delivery Device Able to Deliver Any Liquid FDA Approved Transdermal Drug. https://www.usaspending.gov/award/CONT_AWD_75N91023C00059_7529_-NONE-_-NONE-/
- 75A50123C00043 (definitive contract): -$536,094, Barda - Aspr / Daappo / Barda DCMA. Research and Development - Aoi #20 for the Development of a Low-Cost, Integrated, Lateral Flow Immunoassay and Blood Collection Diagnostic for Ebolavirus. https://www.usaspending.gov/award/CONT_AWD_75A50123C00043_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/satio-inc-h8wfvflrqyn3.